BRIEF published on 08/24/2026 at 08:05, 20 days 15 hours ago Valerio Therapeutics Acquires Etherna and Secures Financing Valerio Therapeutics Etherna Immunotherapies RNA Therapeutics Acquisition PIPE Financing Biotech Integration
PRESS RELEASE published on 08/24/2026 at 08:00, 20 days 15 hours ago Inside Information / Operations of the issuer (acquisitions, sales...) Valerio Therapeutics announces acquisition of Etherna Immunotherapies for €30 million enterprise value and €40.25 million PIPE financing. Shareholder approval secured Acquisition Valerio Therapeutics RNA Therapeutics Etherna Immunotherapies PIPE Financing
BRIEF published on 07/16/2026 at 09:12, 1 month 28 days ago Valerio Therapeutics Partners with Abivax for RNA Therapeutics Development Biotechnology Valerio Therapeutics Pipelines RNA Therapeutics Abivax Collaboration
BRIEF published on 07/16/2026 at 09:12, 1 month 28 days ago Valerio Therapeutics and Abivax join forces for innovative therapies Abivax Collaboration Inflammatory Diseases Valerio Therapeutics RNA Therapies
PRESS RELEASE published on 07/16/2026 at 09:07, 1 month 28 days ago Inside Information / Other news releases Valerio Therapeutics partners with Abivax for global collaboration, providing pipeline update on RNA therapeutics. Initial payment up to €2.4 million Abivax Collaboration Valerio Therapeutics Pipeline Update RNA Therapeutics
BRIEF published on 07/01/2026 at 09:27, 2 months 12 days ago Valerio Therapeutics is preparing to acquire Etherna Immunotherapies Valerio Therapeutics Biotechnology Investment Etherna Acquisition RNA Drugs Mergers Of Companies
BRIEF published on 07/01/2026 at 09:27, 2 months 12 days ago Valerio Therapeutics Proposes to Acquire Etherna Immunotherapies Biotechnology Valerio Therapeutics Acquisition Deal RNA Medicines Etherna Immunotherapies
PRESS RELEASE published on 07/01/2026 at 09:22, 2 months 12 days ago Inside Information / Other news releases Valerio Therapeutics announces binding offer to acquire Etherna Immunotherapies, creating global leader in targeted RNA medicines. Strategic move unlocked by leading investors Acquisition Valerio Therapeutics RNA Medicines Targeted Delivery Etherna Immunotherapies
BRIEF published on 06/16/2026 at 19:48, 2 months 27 days ago Valerio Therapeutics Appoints New CEO and Confirms AGM Resolutions Biotechnology CEO Transition Valerio Therapeutics Gilles Besin RNA Medicines
PRESS RELEASE published on 06/16/2026 at 19:43, 2 months 27 days ago Inside Information / Other news releases Valerio Therapeutics appoints Gilles Besin as CEO, approved all resolutions at annual general meeting. Besin brings deep RNA and targeted delivery expertise to drive innovation Annual General Meeting Valerio Therapeutics Gilles Besin RNA Medicines Targeted Delivery
Published on 09/12/2026 at 02:35, 1 day 20 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 2 days ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 2 days 1 hour ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days 6 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 day 5 hours ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 15 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 2 days ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 2 days ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 2 days 3 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 16 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 3 days 3 hours ago Availability of the 2026 Interim Financial Report
